Contact Us

BioMARC secures $3 million from the Department of Defense to advance vaccine development

Fort Collins, CO. March 1, 2017-

Colorado State University’s vaccine manufacturing facility, BioMARC, is using a state-of-the-art system to develop its first drug meant to protect U.S. soldiers from a mosquito-borne pathogen known as Venezuelan equine encephalitis virus that can cause severe illness and death in people.

 

The vaccine development is funded through a $3 million contract with the U.S. Department of Defense, which often supports research to protect soldiers from pathogens that in some cases are considered potential agents of bioterrorism. Venezuelan equine encephalitis virus is among many agents in this category, according to the U.S. Centers for Disease Control and Prevention. Research findings often have broad application in protecting human health.

 

"The vaccines we will be producing will be used in clinical trials in humans," said Dennis Pierro, BioMARC director and an assistant professor in CSU's Department of Microbiology, Immunology and Pathology. "BioMARC has experience in this realm, but it is the first time in our support of the Department of Defense that we will make the vaccines for humans."

 

CSU is a subcontractor on the vaccine project for Battelle, a research organization that works with the DoD’s Medical Countermeasure Systems Joint Vaccine Acquisition Program. One of the program's requirements is to develop vaccines to protect soldiers from aerosolized exposure to viruses.

 

To help with this mission, BioMARC uses a state-of-the-art vaccine system called a Viral Replicon Particle (VRP) that researchers believe results in improved vaccine efficacy. VRPs are new biotechnology tools that better deliver vaccines to the cells in the body and also prompt stronger immune responses.

 

Over the past several years, BioMARC has successfully met milestones, meaning they completed tasks, established by the DoD for several vaccines, including those developed for Ebola and Marburg virus, and Western, Eastern and Venezuelan equine encephalitis viruses.

 

The mosquito-borne viruses can cause severe long-term disease and possibly death in humans, and there are currently no licensed human vaccines or therapeutics approved by the U.S. Food and Drug Administration. Venezuelan equine encephalitis virus can cause fatal neurologic disease in horses and people; it is found predominantly in Central and South America, but has spread to the United States.

 

BioMARC has previously produced products for Mycobacterium tuberculosis, human immunodeficiency virus, and West Nile virus, among other viruses and bacteria. In total, more than a dozen batches of products have been created for human use at BioMARC. A batch can contain thousands of doses of a vaccine.

 

BioMARC’s vaccine work is a critical part of CSU’s end-to-end response to infectious diseases that often arise in the tropics and increasingly cause devastating outbreaks around the globe. CSU, which partners with key federal agencies, provides bench science to illuminate how pathogens work at the molecular level – as well as applied and field research aimed at reducing the global burden of infectious disease.

 

“It is our way of returning on the public investment in education and research," said Raymond Goodrich, executive director of the Infectious Disease Research Center at CSU, which is where BioMARC is housed. “This program is just one example of the unique capabilities of the BioMARC facility, which provides benefits to healthcare communities at the state, national and international level.”

 

About BioMARC

 

BioMARC is a nonprofit Contract Manufacturing Service Unit owned and operated by Colorado State University and created to produce biopharmaceutical products for non-clinical, clinical, and commercial use under Biosafety Level 3 and Biosafety Level 2 containment and Select Agent biosecurity conditions. In addition to manufacturing and testing services, BioMARC offers product and process development services, which includes the creation of development programs focused on implementation of Current Good Manufacturing Practice regulations and scalability issues.

 

BioMARC is housed on CSU's Foothills campus in the Infectious Disease Research Center.

 

About CSU Infectious Disease Research Center

 

The Infectious Disease Research Center provides a secure, state-of-the-art facility for university investigators, government scientists, and industry representatives to collaboratively research the basic biology, biochemistry, molecular biology, and epidemiology of bacteria and viruses that cause human and animal diseases. The Center provides a research environment for developing new scientific discoveries, vaccines, methods of diagnosis, and therapeutic agents for infectious agents. 

Contact Information

Dennis Pierro, PhD                                                     
Director                                                                             
dennis.pierro@colostate.edu
(970) 491-8954
        
Background